ORMP NASDAQ
Credit Risk of going bust: lower than 87% of companies Debt: 0.4% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.00 (down more than 99.9%), Oramed Pharmaceuticals Inc. would be worth roughly what it owes.
Total debt $733K against a stock market value of $169.7M.
Distance to default 12.22 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $249K (short-term plus half of long-term), stock volatility 52.7%; Altman Z'' 10.12. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
New York City, NY 10036
US
Oramed Pharmaceuticals Inc., founded in 2002 and based in New York, New York, specializes in the development of groundbreaking pharmaceutical treatments. Their primary focus is on creating orally ingested capsules or pills for the delivery of polypeptides, particularly aimed at managing diabetes. The company's leading product, ORMD-0801, is an oral insulin capsule that has successfully completed Phase II clinical trials for patients with diabetes. Oramed is also advancing ORMD-0901, an oral glucagon-like peptide-1 (GLP-1) capsule, which has concluded Phase I clinical trials for the treatment of type 2 diabetes. Additionally, an oral leptin capsule for weight loss is currently under development. The firm was originally incorporated as Integrated Security Technologies, Inc., before officially changing its name to Oramed Pharmaceuticals Inc. in April 2006.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Gabay Avraham | S-Sale | 20,000 | $4.51 | 2026-10-01 |
| Hexter Joshua | S-Sale | 30,000 | $4.51 | 2026-10-01 |
| KIDRON NADAV | A-Award | 349,497 | $4.75 | 2026-09-24 |
| KIDRON NADAV | A-Award | 368,765 | — | 2026-09-24 |
| KIDRON NADAV | D-Return | 196,500 | $3.16 | 2026-09-24 |